| Literature DB >> 26421927 |
Martha Tibebu Lemma1, Yohannes Zenebe1, Begna Tulu2, Daniel Mekonnen2, Zewdie Mekonnen3.
Abstract
BACKGROUND: MRSA infections are becoming more prevalent throughout the HIV community. MRSA infections are a challenge to both physicians and patients due to limited choice of therapeutic options and increased cost of care.Entities:
Mesh:
Year: 2015 PMID: 26421927 PMCID: PMC4589400 DOI: 10.1371/journal.pone.0137254
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline demographic data in HIV-infected children who gave skin, nasal and perineal samples, Amhara National Regional State, 2014.
| Variable | Patients, n (%) |
|---|---|
| Female | 176 (44) |
| Type of residence, n (%) | |
| Urban | 397 (99.2) |
| Rural | 3 (0.8) |
| Median age (IQ range) | 10 (4) |
| WHO Stage, n(%) | |
| I | 93 (23.2) |
| II | 139 (34.8) |
| III | 149 (37.2) |
| IV | 19 (4.8) |
| CD4 count, Median (IQR) | |
| Baseline | 322 (392) |
| Most recent | 597 (493) |
| Hospitalization within the past 12 months, n (%) | |
| Yes | 14 (3.5) |
| No | 386 (96.5) |
| History of antibiotic use in the past 3 months, n(%) | |
| Yes | 33 (8.2) |
| No | 367 (91.8) |
| History of treatment with HAART, n (%) | |
| Taking HAART | 318 (79.5) |
| Not on ARVs | 82 (20.5) |
| Months on HAART, Mean | 36.24 |
| History of ARV treatment failure, n (%) | |
| Yes | 10 (2.5) |
| No | 390 (97.5) |
| Co-trimoxazole Preventive Therapy, n (%) | |
| Yes | 318 (79.5) |
| No | 82 (20.5) |
| Months on CPT, Mean | 34.91 |
Fig 1Numbers of S. aureus clinical isolates by type of specimen among 400 HIV-infected children, Amhara National Regional State, 2014.
Correlation between Variables and Colonization by S. aureus among 400 HIV-Infected Pediatric Patients, Amhara National Regional State, 2014.
| Covariate | Odds ratio | p-value | 95% CI |
|---|---|---|---|
| Gender (Male/Female) | 0.5869 | 0.0155 | 0.3812–0.9036 |
| Age Groups | 0.9364 | 0.858 | 0.4557–1.9242 |
| History of hospitalization in the past 3 months | 0.7334 | 0.6398 | 0.2002–2.6871 |
| History of antibiotic therapy in the previous 3 months (yes/No) | 2.3126 | 0.0329 | 1.0707–4.9948 |
| Initiation of ART | 0.818 | 0.5594 | 0.4167–1.6059 |
| Type of HAART regimen | 0.9062 | 0.0928 | 0.8078–1.0165 |
| Duration on HAART | 1.2616 | 0.069 | 0.9821–1.6208 |
| Initiation of CPT | 1.3286 | 0.4248 | 0.6612–2.6695 |
| Duration on CPT | 1.3377 | 0.167 | 0.8854–2.0210 |
| History of ART failure | 0.6613 | 0.5425 | 0.1748–2.5024 |
| Baseline WHO stage | 1.0798 | 0.5545 | 0.8370–1.3931 |
| Most recent WHO stage | 0.9988 | 0.9845 | 0.8855–1.1266 |
| Baseline CD4Category | 0.7745 | 0.2294 | 0.5106–1.1749 |
| Most Recent CD4Category | 0.5739 | 0.044 | 0.3343–0.9851 |
*CD4T-cell count of 350 x 106 cells / L or more per ml versus CD4T-cell counts under 350 x 106 cells / L
Correlation between Variables and Colonization by MRSA among 400 HIV-Infected Pediatric Patients, Amhara National Regional State, 2014.
| Covariate | Odds ratio | p-value | 95% CI |
|---|---|---|---|
| Gender (Male/Female) | 0.9772 | 0.9324 | 0.5733–1.6657 |
| Age Groups | 1.0104 | 0.9615 | 0.6633–1.5392 |
| History of hospitalization in the past 3 months | 1.0297 | 0.9704 | 0.2193–4.8352 |
| History of antibiotic therapy in the previous 3 months (yes/No) | 2.608 | 0.027 | 0.1010–2.5420 |
| Initiation of ART | 1.0167 | 0.9696 | 0.4346–2.3786 |
| Type of HAART regimen | 0.9679 | 0.6562 | 0.8383–1.1175 |
| Duration on HAART | 0.9472 | 0.7921 | 0.6329–1.4176 |
| Initiation of CPT | 0.9714 | 0.93 | 0.5090–1.8541 |
| Duration on CPT | 1.0226 | 0.9367 | 0.5886–1.7767 |
| History of ART failure | 0.394 | 0.2076 | 0.0926–1.6771 |
| Baseline WHO stage | 0.863 | 0.4037 | 0.6107–1.2195 |
| Most recent WHO stage | 1.0877 | 0.305 | 0.9263–1.2771 |
| Baseline CD4 Category | 0.8436 | 0.5508 | 0.4825–1.4751 |
| Most Recent CD4Category | 0.6809 | 0.2547 | 0.3514–1.3193 |
*CD4T-cell count of 350 x 106 cells / L or more per ml versus CD4T-cell counts under 350 x 106 cells / L
Antibiotic co-resistance pattern of MRSA isolated from HIV positive pediatric patients, Amhara National Regional state, 2014.
| Antibiotic | Per cent | 95% CI |
|---|---|---|
| Chloramphenicol | 6 | 0.32–2.72 |
| Ceftriaxone | 20.9 | 2.00–5.94 |
| Ciprofloxacin | 23.9 | 2.38–6.55 |
| Clindamycin | 7.6 | 0.46–3.06 |
| Co-trimoxazole | 5.25 | 3.36–8.04 |
| Erythromycin | 23.9 | 2.38–6.55 |
| Tetracycline | 72.1 | 9.28–15.96 |